Daiichi Sankyo Sees Strong Growth Despite One‑Off Costs
Daiichi Sankyo says its underlying business remains strong despite a one‑time expense and conservative earnings guidance that came in below…
Daiichi Sankyo says its underlying business remains strong despite a one‑time expense and conservative earnings guidance that came in below…
AstraZeneca Plc and Daiichi Sankyo’s drug Datroway helped breast cancer patients with a particularly hard to treat form of the…
The surging bond yields that have saddled Japan’s insurers with billions of dollars in unrealized losses will weaken because they…